NEW YORK (
) hit a new 52-week low Friday as it is currently trading at $14.98, below its previous 52-week low of $15 with 3.4 million shares traded as of 2:50 p.m. ET. Average volume has been one million shares over the past 30 days.
NuVasive has a market cap of $681.8 million and is part of the
industry. Shares are down 30.6% year to date as of the close of trading on Thursday.
NuVasive, Inc., a medical device company, engages in the design, development, and marketing of minimally disruptive surgical products and procedures for the spine. Its products are used in applications for spine fusion surgery. The company has a P/E ratio of 9.2, equal to the average health services industry P/E ratio and below the S&P 500 P/E ratio of 17.7.
- Practice your NUVA trading strategies and win cash in our stock game.
TheStreet Ratings rates NuVasive as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and generally poor debt management. You can view the full
or get investment ideas from our